# US 12,595,244 B2 · Small molecule inhibitors of mammalian SLC6A19 function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,595,244 B2
- Document ID: US12595244B2
- Status: Granted
- Kind: B2
- Application number: 19/224,188
- Filed: 2025-05-30
- Published: 2025-09-18
- Granted: 2026-04-07
- Earliest claimed: 2021-03-10
- Assignees: Jnana Therapeutics Inc.
- Applicants: Jnana Therapeutics Inc.
- Inventors: Dean G. Brown; Giovanni Muncipinto; Joshua Ethan Zweig; Long Vo Nguyen
- Web page: https://patentgrep.com/patent/US12595244B2

## CPC

- C07D 211/56: Nitrogen atoms (nitro radicals C07D211/38)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 211/58: attached in position 4
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.

## Claims

### Claim 1

A compound having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 having the structure: